IL6 and acute myeloid leukemia: Neoplastic MSCs in MDS and AML decrease tumor immunosurveillance through downregulation of costimulatory molecules (CD40, CD80, and CD86) [91], increase immunosuppressive cytokine production (TGFβ, IL-6, and HGF) with consequent T cell and DC suppression and Tregs and MSC type 2 increases.